{"entity":{"id":"nihon-medi-physics","kind":"company","name":"Nihon Medi-Physics","aka":["Nihon Medi-Physics Co., Ltd.","NMP"],"tldr":"Japan's largest maker of radioactive tracers for scans, now wholly owned by GE HealthCare.","summary":"Nihon Medi-Physics was incorporated on 20 March 1973 and is based at Shinsuna, Koto-ku, Tokyo. Its stated business is the \"research, development, manufacture, sale, purchase and import/export of radioactive pharmaceuticals\". It holds the Japanese approvals for several of the diagnostic agents in this corpus, each dated in the PMDA's own English list: DaTscan (ioflupane I-123) in September 2013, Vizamyl (flutemetamol F-18) in September 2017 and Axumin (fluciclovine F-18) in March 2021.\n\nOwnership changed in 2025. GE HealthCare had held 50 per cent since acquiring Amersham in 2004; on 31 March 2025 it completed the purchase of the remaining 50 per cent from Sumitomo Chemical, making NMP a wholly owned subsidiary and giving GE HealthCare direct control of the Japanese radiopharmaceutical channel. In September 2025 Lantheus and GE HealthCare announced an exclusive licence for PYLARIFY (piflufolastat F-18) in Japan, which is how a US PSMA tracer reaches the Japanese market.","asOf":"2026-09-22","links":[{"label":"Company overview (incorporated 20 March 1973; shareholder GE HealthCare)","url":"https://www.nmp.co.jp/eng/profile/about.html"},{"label":"GE HealthCare completes acquisition of Nihon Medi-Physics","url":"https://www.gehealthcare.com/en-us/about/newsroom/press-releases/ge-healthcare-completes-acquisition-of-nihon-medi-physics-nmp-a-leading-radiopharmaceutical-company-in-japan"},{"label":"PMDA list of approved drugs (April 2004 onwards)","url":"https://www.pmda.go.jp/files/000281190.pdf"}],"tags":[],"related":["ge-healthcare","i-123-ioflupane","f-18-flutemetamol","fluciclovine-f18","pylarify","jsnm","pmda","f-18","i-123"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo, Japan","country":"JP","companyType":"radiopharma","website":"https://www.nmp.co.jp/eng/","founded":1973,"stage":"acquired","investors":[],"funding":[],"acquiredBy":"ge-healthcare"},"route":"/companies/nihon-medi-physics/","neighbours":{"company":[{"id":"ge-healthcare","kind":"company","name":"GE HealthCare","route":"/companies/ge-healthcare/"}],"drug":[{"id":"fluciclovine-f18","kind":"drug","name":"Fluciclovine F-18","route":"/drugs/fluciclovine-f18/"},{"id":"f-18-flutemetamol","kind":"drug","name":"Flutemetamol F-18","route":"/drugs/f-18-flutemetamol/"},{"id":"i-123-ioflupane","kind":"drug","name":"Ioflupane I-123","route":"/drugs/i-123-ioflupane/"},{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/"}],"institution":[{"id":"jsnm","kind":"institution","name":"Japanese Society of Nuclear Medicine","route":"/institutions/jsnm/"},{"id":"pmda","kind":"institution","name":"Pharmaceuticals and Medical Devices Agency","route":"/institutions/pmda/"}],"isotope":[{"id":"f-18","kind":"isotope","name":"Fluorine-18","route":"/isotopes/f-18/"},{"id":"i-123","kind":"isotope","name":"Iodine-123","route":"/isotopes/i-123/"}]}}